title: United States' factor XI-deficiency patients need a safer treatment.
abstract: A replacement factor for Factor XI with is virally inactivated is not available in the U.S. Elsewhere an inactivated concentrate has been used. A review of the experience over 15 years suggests that this product is safe and effective and suggests its potential use in the U.S. The most serious complication of the factor was a slight increase in DIC and thrombotic events.
authors.affiliation: Mount Sinai School of Medicine, New York, New York 10029, USA. Louis.aledort@mssm.edu
authors.forename: Louis M
authors.initials: LM
authors.lastname: Aledort
authors.forename: Jenny
authors.initials: J
authors.lastname: Goudemand
mesh_terms: D001781:Blood Component Removal; D019468:Disease Management; D005173:Factor XI Deficiency / Q000453:epidemiology / Q000628:therapy*; D006301:Health Services Needs and Demand; D006801:Humans; D010949:Plasma; D014481:United States; D038301:Virus Inactivation